Humana Inc. (HUM) Shares Bought by Dynamic Technology Lab Private Ltd
Dynamic Technology Lab Private Ltd raised its position in Humana Inc. (NYSE:HUM) by 106.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,780 shares of the insurance provider’s stock after buying an additional 3,498 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Humana were worth $1,651,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of HUM. Janus Henderson Group PLC boosted its holdings in Humana by 7,848.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock worth $377,192,000 after buying an additional 1,547,866 shares during the last quarter. FMR LLC boosted its holdings in Humana by 29.3% in the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after buying an additional 1,479,210 shares during the last quarter. Koch Industries Inc. acquired a new position in shares of Humana during the 2nd quarter worth approximately $404,000. Acadian Asset Management LLC boosted its holdings in shares of Humana by 1,340.0% during the 2nd quarter. Acadian Asset Management LLC now owns 420,578 shares of the insurance provider’s stock worth $101,199,000 after purchasing an additional 391,372 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in shares of Humana by 39.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock worth $326,910,000 after purchasing an additional 386,162 shares during the last quarter. Institutional investors own 96.15% of the company’s stock.
HUM has been the topic of several recent research reports. ValuEngine cut Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Credit Suisse Group lowered their target price on Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. BidaskClub upgraded Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Jefferies Group LLC restated a “hold” rating and set a $257.00 target price on shares of Humana in a report on Friday, October 13th. Finally, BMO Capital Markets boosted their target price on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. Thirteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $252.81.
Shares of Humana Inc. (NYSE HUM) traded down $2.45 during midday trading on Friday, reaching $233.46. The company’s stock had a trading volume of 1,030,000 shares, compared to its average volume of 1,256,769. The stock has a market capitalization of $33,352.10, a price-to-earnings ratio of 19.92, a price-to-earnings-growth ratio of 1.60 and a beta of 0.91. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana Inc. has a 52 week low of $186.25 and a 52 week high of $264.56.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.18 earnings per share. analysts predict that Humana Inc. will post 11.63 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s dividend payout ratio is currently 12.59%.
In other news, VP Timothy S. Huval sold 7,803 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the sale, the vice president now owns 8,831 shares of the company’s stock, valued at $2,279,634.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the sale, the insider now directly owns 18,042 shares in the company, valued at approximately $4,672,878. The disclosure for this sale can be found here. Insiders have sold 20,660 shares of company stock worth $5,319,600 in the last ninety days. Corporate insiders own 0.80% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.